+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Host mechanisms: are they the key to the various clinical outcomes of Helicobacter pylori infection?



Host mechanisms: are they the key to the various clinical outcomes of Helicobacter pylori infection?



Italian Journal of Gastroenterology and Hepatology 29(4): 375-382



It is unclear why Helicobacter pylori produces different diseases in different persons. High and low acid secretion rates probably contribute to duodenal ulceration and gastric carcinogenesis, respectively. Both of these changes seem to be corrected by eradicating Helicobacter pylori. We are therefore exploring the basic mechanisms and asking why patients react differently? Helicobacter pylori products and certain cytokines released in Helicobacter pylori gastritis release gastrin from G-cells but inhibit parietal cells. Also tumour necrosis factor alpha inhibits somatostatin-cells and interleukin 1 beta inhibits enterochromaffin-like cells. The net result is that antral gastritis tends to increase, whilst corpus gastritis tends to decrease acid secretion. Corpus atrophy further lowers acid through loss of parietal cells. Factors postulated to increase corpus gastritis include host genetics, early acquisition of Helicobacter pylori, more aggressive strains, poor general health and diets high in salt or lacking in antioxidant vitamins. Further research should address the interaction of bacterium, host and environment with a view to preventing the serious clinical outcomes.

(PDF emailed within 1 workday: $29.90)

Accession: 046274852

Download citation: RISBibTeXText

PMID: 9476195


Related references

Host factors are important in determining clinical outcomes of Helicobacter pylori infection. Journal of Gastroenterology 41(1): 1-9, 2006

Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Canadian Journal of Gastroenterology 18(9): 547-554, 2004

Acute gastric mucosal lesions caused by acute Helicobacter pylori infection -clinical outcomes of six cases and problems in the diagnosis of H. pylori infection. Nihon Shokakibyo Gakkai Zasshi 111(5): 899-908, 2014

Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?. Medical Science Monitor 7(1): 137-141, 2001

Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. Clinical Science 128(4): 281-281, 2015

Host determinants of Helicobacter pylori infection and its clinical outcome. Helicobacter 4(3): 185-197, 1999

Clinical outcome of patients with Helicobacter pylori infection: the bug, the host, or the environment?. Postgraduate Medical Journal 82(967): 338-342, 2006

Clinical outcomes of Helicobacter pylori infection in relation to vacA. 2007

T1641 The Role of Homb in the Clinical Outcomes of Helicobacter pylori Infection. Gastroenterology 136(5): A-548-A-549, 2009

Differential inflammatory response to Helicobacter pylori infection: etiology and clinical outcomes. Journal of Inflammation Research 8: 137-147, 2015

Guidelines for clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. Gut 41 Suppl 2: S1-S9, 1997

Clinical significance of anti-Helicobacter pylori antibody in the diagnosis of Helicobacter pylori infection in chronic gastritis. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 66(11): 1597-1598, 1992

Prevalence and clinical importance of Helicobacter pylori infection in patients after partial gastric resection for peptic ulcer disease. A prospective evaluation of Helicobacter pylori infection on 50 resected patients compared with matched nonresected controls. Zeitschrift für Gastroenterologie 37(2): 127-132, 1999

Helicobacter pylori infection: CagA-specific antibodies are associated with clinical outcome, but not with HLA-class II polymorphisms of the host. International Journal of Medical Microbiology 292(7-8): 537-540, 2003

Clinical usefulness of virulence factors of Helicobacter pylori as predictors of the outcomes of infection. What is the evidence?. Scandinavian Journal of Gastroenterology 38(9): 905-915, 2003